Phase I Program

Note: Other Phase 1 Studies may be open at the Knight, please click here to view

- IRB# 17674: Loxo-195 in fusion-NTRK (previously treated) solid tumors
- IRB# 18164: A Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
- IRB# 16676: BLU-667 in thyroid cancer, non-small cell lung cancer and advanced solid tumors
- IRB# 21548: A Phase 1 Study of AMG 650 in Subjects With Advanced Solid Tumors
- IRB# 21819: A Phase 1-2 Study of ASTX029 in Subjects With Advanced Solid Tumors
- TNBC, HGSOC, Endometrial, and advanced solid tumor withTp53 mutation
- Solid tumors with gene aberrations in the mitogen-activated protein kinase (MAPK) pathway

http://www.ohsu.edu/research/rda/so/knight.php
IRB 22580
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

No known mutation, phase 1; TREM1 expression phase 2

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

TREM1 expression phase 2

IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard, therapy exists

IRB 23966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Solid tumors with a BRAF fusion alteration

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a MYC gene mutation

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 22863
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

TREM2 expression phase 2

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 22925
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a BRAF fusion alteration

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

IRB 22966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Solid tumors with a BRAF fusion alteration

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a MYC gene mutation

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

No known mutation, phase 1; TREM1 expression phase 2

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

TREM2 expression phase 2

IRB 22863
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 22966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard, therapy exists

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a BRAF fusion alteration

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

No known mutation, phase 1; TREM1 expression phase 2

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

TREM2 expression phase 2

IRB 22863
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 22966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard, therapy exists

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a BRAF fusion alteration

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

IRB 21998
A Phase 1/2 Open-label study to evaluate PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

No known mutation, phase 1; TREM1 expression phase 2

IRB 22223
A Phase 1a/1b Open-Label Study to Evaluate PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Locally-advanced or metastatic solid tumor with an NRG1 gene fusion

IRB 22580 CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors

TREM2 expression phase 2

IRB 22863
A Study of PY314 in Subjects With Advanced Solid Tumors

IRB 22925
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors

Microsatellite Stable (MSS) colorectal, ovarian, and endometrial

IRB 22966
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Advanced solid tumor that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective, or if no further standard, therapy exists

IRB 22902
A PHASE 2, SUBPROTOCOL OF DAY101 MONOTHERAPY FOR PATIENTS WITH RECURRENT, PROGRESSIVE, OR REFRACTORY SOLID TUMORS WITH ACTIVATING BRAF GENE FUSION

Solid tumors with a BRAF fusion alteration

IRB 22986
An open-label study to evaluate VPI152 (BAY 1251152) alone or in combination with pembrolizumab in subjects with advanced cancer

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

4/28/2022
http://www.ohsu.edu/research/rda/so/knight.php